Biotech Series C Investors & VC Firms

600 firms in this list, with a median first check of $1M. 112 of them lead rounds. Generated from verified public data and updated continuously.

Fund	FoxScore	HQ	Invests	Stage	Check	CRM
PM PM Equity Partner AGACCODS9 people	88🔒	Lausanne	CH	Series A–Growth	$2M – $50M	+ Add to CRM
SO Soul Ventures BSWHBSJK12 people	88🔒	—	US	Series C–Late Stage	—	+ Add to CRM
VE Vesalius Biocapital III Partners SàRL CSGGMLCW12 people	88🔒	Contern	LU	Seed–Late Stage	$10.8M	+ Add to CRM
ID IDG Capital JNMLQZXL5 people	88🔒	Hong Kong	HK	Pre-Seed–Late Stage	$3M – $200M	+ Add to CRM
OX Oxford Investment Consultants LLP GRPLRHCH11 people	88🔒	Oxford	GB	Seed–Late Stage	—	+ Add to CRM
CA Cancer Fund ALABJRAD9 people	88🔒	Phoenix	US	Seed–Series C	—	+ Add to CRM
SA Sambrinvest EDFCGGMS11 people	88🔒	Charleroi	BE	Series A–Late Stage	—	+ Add to CRM
PA Pandect Bioventures MXMTWHRW10 people	88🔒	Woodside	US	Seed–Late Stage	—	+ Add to CRM
DE Deep Insight BBEKIKNC6 people	88🔒	Tel Aviv	IL	Pre-Seed–Late Stage	—	+ Add to CRM
MI Mithril Capital Management PTARCM3 people · Follows rounds	88🔒	Austin	US	Series B–Late Stage	—	+ Add to CRM
TU TusStar	88🔒	Beijing	CN	Pre-Seed–Growth	—	+ Add to CRM
GE Georgian APEWEKFS11 people	88🔒	Toronto, Ontario	CA	Series B–Late Stage	$25M – $100M	+ Add to CRM
OC OCV Partners RRALCBHZ5 people · Leads rounds	88🔒	Los Angeles	US	Pre-Seed–Late Stage	—	+ Add to CRM
TE Tenacity Ventures GBRRKRRA5 people · Leads rounds	88🔒	Bengaluru	IN	Seed–Growth	$10M	+ Add to CRM
VE Vesalius Biocapital Partners APCSGMSV5 people · Leads rounds	88🔒	Luxembourg	LU	Seed–Late Stage	$11M	+ Add to CRM
KO Kolon Investment, Inc.	88🔒	Seoul	KR	Seed–Late Stage	$3K – $22M	+ Add to CRM
SH Shenzhen Capital Group DZSLXW3 people	88🔒	Shenzhen	CN	Seed–Growth	$1.5M – $156M	+ Add to CRM
PA Panakes Partners ABDSFLBC11 people · Follows rounds	88🔒	Milan	IT	Seed–Late Stage	—	+ Add to CRM
SY Syridex Bio SSVPJACW11 people	88🔒	Princeton	US	Pre-Seed–Late Stage	—	+ Add to CRM
BR Bridge to Growth GGMBSSFW4 people	88🔒	Berlin	DE	Series A–Late Stage	$1.1M – $5.4M	+ Add to CRM
TR Triatomic Capital JHPZSHWV6 people · Leads rounds	88🔒	Palo Alto	US	Seed–Series C	$100K – $1M	+ Add to CRM
RO Roche Venture Fund AHDESGCN6 people	88🔒	Basel	CH	Seed–Growth	$648K – $3.2M	+ Add to CRM
CL Clal Biotechnology Industries AALNAFBG8 people	88🔒	Tel Aviv	IL	Seed–Late Stage	—	+ Add to CRM
JS JSD Capital, LLC JMJSAHGM8 people	88🔒	New York	US	Seed–Late Stage	$10M	+ Add to CRM

PM Equity Partner

LausanneSeries A–Growth$2M – $50M

AGACCODS9 people

Soul Ventures

Series C–Late Stage

BSWHBSJK12 people

Vesalius Biocapital III Partners SàRL

ConternSeed–Late Stage$10.8M

CSGGMLCW12 people

IDG Capital

Hong KongPre-Seed–Late Stage$3M – $200M

JNMLQZXL5 people

Oxford Investment Consultants LLP

OxfordSeed–Late Stage

GRPLRHCH11 people

Cancer Fund

PhoenixSeed–Series C

ALABJRAD9 people

Sambrinvest

CharleroiSeries A–Late Stage

EDFCGGMS11 people

Pandect Bioventures

WoodsideSeed–Late Stage

MXMTWHRW10 people

Deep Insight

Tel AvivPre-Seed–Late Stage

BBEKIKNC6 people

Mithril Capital Management

AustinSeries B–Late Stage

PTARCM3 people

TusStar

BeijingPre-Seed–Growth

Georgian

Toronto, OntarioSeries B–Late Stage$25M – $100M

APEWEKFS11 people

OCV Partners

Los AngelesPre-Seed–Late Stage

RRALCBHZ5 people

Tenacity Ventures

BengaluruSeed–Growth$10M

GBRRKRRA5 people

Vesalius Biocapital Partners

LuxembourgSeed–Late Stage$11M

APCSGMSV5 people

Kolon Investment, Inc.

SeoulSeed–Late Stage$3K – $22M

Shenzhen Capital Group

ShenzhenSeed–Growth$1.5M – $156M

DZSLXW3 people

Panakes Partners

MilanSeed–Late Stage

ABDSFLBC11 people

Syridex Bio

PrincetonPre-Seed–Late Stage

SSVPJACW11 people

Bridge to Growth

BerlinSeries A–Late Stage$1.1M – $5.4M

GGMBSSFW4 people

Triatomic Capital

Palo AltoSeed–Series C$100K – $1M

JHPZSHWV6 people

Roche Venture Fund

BaselSeed–Growth$648K – $3.2M

AHDESGCN6 people

Clal Biotechnology Industries

Tel AvivSeed–Late Stage

AALNAFBG8 people

JSD Capital, LLC

New YorkSeed–Late Stage$10M

JMJSAHGM8 people

Data sourced from public filings and firms' own websites — see our methodology.